Paul V. Beum - Search Results

Year	Number of Results
2003	1
2004	3
2005	2
2006	4
2007	1
2008	3
2009	2
2010	1
2011	2
2012	1
2013	1
2014	1
2024	0

1

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Beurskens FJ, et al. Among authors: beum pv. J Immunol. 2012 Apr 1;188(7):3532-41. doi: 10.4049/jimmunol.1103693. Epub 2012 Feb 24. J Immunol. 2012. PMID: 22368276 Free PMC article. Clinical Trial.

2

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A. Aue G, et al. Among authors: beum pv. Haematologica. 2010 Feb;95(2):329-32. doi: 10.3324/haematol.2009.012484. Epub 2009 Aug 13. Haematologica. 2010. PMID: 19679883 Free PMC article. Clinical Trial.

3

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Kennedy AD, et al. Among authors: beum pv. J Immunol. 2004 Mar 1;172(5):3280-8. doi: 10.4049/jimmunol.172.5.3280. J Immunol. 2004. PMID: 14978136

4

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.

DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP. DiLillo DJ, et al. Among authors: beum pv. Mol Immunol. 2006 Mar;43(7):1010-9. doi: 10.1016/j.molimm.2005.05.003. Epub 2005 Jun 14. Mol Immunol. 2006. PMID: 15961157

5

Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.

Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Beum PV, et al. J Immunol Methods. 2004 Nov;294(1-2):37-42. doi: 10.1016/j.jim.2004.08.004. J Immunol Methods. 2004. PMID: 15604014

6

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.

Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH, Taylor RP, Wiestner A. Mo CC, et al. Among authors: beum pv. Haematologica. 2013 Aug;98(8):1259-63. doi: 10.3324/haematol.2012.080929. Epub 2013 May 28. Haematologica. 2013. PMID: 23716541 Free PMC article. Clinical Trial.

7

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE. Zent CS, et al. Among authors: beum pv. Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723493 Free PMC article. Clinical Trial.

8

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP. Beum PV, et al. J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12. J Immunol. 2011. PMID: 21841127

9

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP. Beum PV, et al. Eur J Immunol. 2011 Aug;41(8):2436-46. doi: 10.1002/eji.201041204. Epub 2011 Jul 4. Eur J Immunol. 2011. PMID: 21674476 Free article.

10

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.

Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Beum PV, et al. J Immunol. 2008 Dec 1;181(11):8120-32. doi: 10.4049/jimmunol.181.11.8120. J Immunol. 2008. PMID: 19018005

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year